Biotech Values

[DewDiligence]

Thanks for the ISRG update. I can confirm from the reports by such companies as AGN, SYK, and ZMH that elective procedures have been relatively weak during the past year or so, although they have been improving lately. For instance, AGN’s LapBand (which I just posted about in #msg-60021023) has been especially hard hit during this period despite its being heavily promoted.

wasn't it you that said, "The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”?

That sounds familiar :- )